Brandon Capital

Heart Metabolics Limited is a pharmaceutical company focused on developing therapies for hypertrophic cardiomyopathy (HCM), a condition where the heart muscle thickens, making it harder for blood to leave the heart and often leading to heart failure or sudden death. With over 100,000 cases in the United States alone, HCM can be particularly severe in young adults and athletes. Current cardiovascular drugs do not help all patients, highlighting a significant medical need. Heart Metabolics is addressing this by developing perhexiline, an approved drug in Australia and New Zealand for angina, as a therapeutic for all types of HCM. The company plans to conduct clinical trials in the U.S. and seek FDA approval for perhexiline as an orphan drug, which it has already designated.

Amaroq Therapeutics is a biotechnology company that develops cancer therapies targeting long non‑coding RNAs, a recently discovered class of RNA molecules. The company’s platform is based on research originating from the University of Otago in Dunedin, New Zealand, and it focuses on treating common solid tumours such as breast, colorectal and liver cancer. By using long non‑coding RNAs as therapeutic targets and diagnostic markers, Amaroq aims to create next‑generation treatments that improve patient outcomes.